Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2015: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

January 2015 Scleroderma News

FDA Approves Cytori U.S. Pivotal Scleroderma Trial. The STAR trial will begin enrolling in 2015 and will include 80 patients, in up to 12 centers in the United States. The trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of a single administration of Cytori's lead cellular therapeutic, ECCS-50, in scleroderma patients with hand dysfunction. MarketWatch, 01/12/2015. (Also see Scleroderma Clinical Trials: ADRC Injections/STAR)

Intravenous Immunoglobulin (IVIG) May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous Systemic Sclerosis (dcSSc). IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies. PubMed, J Rheumatol, 11/29/2014. (Also see IVIg)

Antinuclear antibody negative systemic sclerosis. SSc patients who are ANA negative constitute a distinct subset of SSc with less vasculopathy, a greater proportion of males and possibly, more frequent lower gastrointestinal involvement. Seminars in Arthritis and Rheumatism, 11/28/2014. (Also see Antibodies in Systemic Scleroderma)

Association Between Nailfold Capillaroscopy (NVC) Findings and Pulmonary Function Tests in Patients with Systemic Sclerosis (SSc). Prospective studies are warranted to determine whether NVC is useful for studying pulmonary function in SSc. PubMed, J Rheumatol, 11/15/2014. (Also see Nailfold Capillaroscopy)

The Effects of Respiratory Muscle Weakness and Pulmonary Involvement on Functional Status, Fatigue and Health Related Quality of Life (HRQoL) in Patients With Systemic Sclerosis. A comprehensive pulmonary rehabilitation program including respiratory muscle exercises should be designed to improve functional status, HRQoL, and fatigue in patients with systemic sclerosis. Archives of Rheumatology, November 2014. (Also see Quality of Life (QOL) with Scleroderma)

Vascular Biomarkers and Correlation with Peripheral Vasculopathy in Systemic Sclerosis. Vascular biomarkers could become useful predictive factors of vascular damage in SSc, allowing an earlier management of vascular complications. PubMed, Autoimmun Rev, 12/04/2014. (Also see Biomarkers in Vascular Disease)

Trabecular Bone Score (TBS) in Female Patients with Systemic Sclerosis (SSc): Comparison with Rheumatoid Arthritis and Influence of Glucocorticoid (GC) Exposure. SSc-related bone involvement is characterized by an impairment in bone quality in addition to reduced bone quantity, and TBS can identify the negative effect of GC on bone microarchitecture. PubMed, J Rheumatol, 12/01/2014. (Also see Osteoporosis and Scleroderma and Osteoporosis and Glucocorticoids, Steroids (Prednisone)

Advances in the evaluation and management of esophageal disease of systemic sclerosis (SSc). In addition to reviewing gastroesophageal reflux disease management in patients with SSc, present and potential uses of endoscopy, reflux monitoring, manometry, impedance planimetry, and endoscopic ultrasound are discussed. PubMed, Curr Rheumatol Rep, 2015 Jan;17(1):475. (Also see Heartburn, GERD and Scleroderma)

Borderline pulmonary arterial pressure (BoPAP) in systemic sclerosis patients: a post–hoc analysis of the DETECT study. In this exploratory post–hoc analysis of the DETECT study population patients with BoPAP could be distinguished from patients with normal mean pulmonary artery pressures and pulmonary arterial hypertension. PubMed, Arthritis Res Ther, 2014 Dec 10;16(6):493. (Also see Pulmonary Hypertension)

Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis (SSc) Pathogenesis. Numerous studies have implicated oxidative stress in SSc pathogenesis, suggesting a plausible mechanism in which excessive oxidative stress induces cellular senescence and that the molecular events play an important role in the fibrotic and fibroproliferative vasculopathy characteristic of SSc. PubMed, Curr Rheumatol Rep, 2015 Jan;17(1):473. (Also see Causes of Scleroderma: Fibroblasts)

Systemic sclerosis (SSc) induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Compared to healthy controls, SSc patients had significantly smaller brachial artery diameter and blunted peripheral vascular reactivity and endothelial function. PubMed, Clin Rheumatol, 12/16/2014. (Also see Vascular Involvement in Systemic Scleroderma)

Go to Scleroderma Medical News: Main Page

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.